Today's Must Read
Comcast (CMCSA) to Benefit From Gigabit Internet Rollout
Teva (TEVA) Beats on 2Q Earnings & Revenue, Maintains View
Friday, August 19, 2016
We are featuring 16 research reports in today's Research Daily, including reports on Verizon (VZ), Comcast (CMCSA) and Teva Pharmaceutical (TEVA).
Verizon shares have been weak lately, but they continued to benefit from investors' great demand for yield (it provides a juicy dividend, currently yiedling in excess of 4%). But Verizon is more than safe and stable dividend. They are actively investing into related spaces that add to their core telecom leadership. The move into online content delivery, mobile video and online advertising, with the recent Yahoo (YHOO) deal as part of that strategy. (Youcan read the full research report on Verizon here>>)
Comcast's continued momentum (the stock is up 20% year-to-date) reflects the strength in its Cable business and significant improvement in the NBC Universal segment. The deals to acquire DreamWorks Animation and Icontrol Networks bode well and should help fend off competition. Also, Comcast is investing heavily in its theme park business. The company has forayed into the over-the-top video delivery market with the launch of its Internet TV service “Stream”. (You can read the full research report on Comcast here>>)
Teva Pharmaceutical shares have struggled this year as a result of investors' concerns on the generic drug maker's pipeline and stiff competitive pressures in the space. These issues notwithstanding, the analyst likes the Actavis Generics acquisition, which will help the company strengthen its position in key generic markets. Teva continues to progress with its branded and generics drugs pipeline and is also looking to strengthen its biosimilar pipeline. (You can read the full research report on TEVA here>>)
You can find all of today's stock research reports here >>>
Today's Private Buys & Sells from Zacks Research
While we share the above news with the public, our sensitive recommendations are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premium subscribers and manages the Zacks Focus List and Top 10 portfolios.
If you want an email notification each time Sheraz publishes a new article, please click here >>